Literature DB >> 16343894

Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation.

Bénédicte Brichard1, Michel Heusterspreute, Patrick De Potter, Christophe Chantrain, Christiane Vermylen, Catherine Sibille, Jean-Luc Gala.   

Abstract

Conclusive identification of RB1 mutations in retinoblastoma is predicted to improve the clinical management of affected children and relatives. However, despite clear clinical benefits, RB1 screening remains difficult, most of the alterations being unique and randomly distributed throughout the entire coding sequence. In this report, we present the results of a constitutional RB1 analysis undertaken in our institution over the last four years. The detection of RB1 gene deletion or mutation was performed by Southern blot and sequence analyses in 73 patients (including three families with 2, 3 and 3 probands, respectively). Complementary constitutional chromosome and fluorescent in situ hybridization (FISH) analyses of RB1 gene were applied in cases where hereditary retinoblastoma was suspected despite negative detection. Altogether, germline abnormalities were found in 11% (4/36 patients) of sporadic unilateral retinoblastoma (median age, 21.5 months) and 86% (32/37 patients) of sporadic bilateral or positive familial history retinoblastoma (median age, 5 months). The spectrum of germline alterations found in 31 distinct families included 12 nonsense mutations (39%); 10 point insertions or deletions with frameshift (32%); 4 mutations and 1 deletion affecting splice sites (16%); 2 missense mutations (6%); and 2 large deletions (6%). A total of 15 mutations have not been previously reported. In this small series, splicing mutations were associated with bilateral disease whilst most of the frameshift mutations were identified in patients with an early age at diagnosis, bilateral disease or hereditary forms of the disease. This study confirms that screening for constitutional RB1 mutation should become an integral part of current management of any patient affected by retinoblastoma irrespective of the tumour laterality and familial background.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16343894     DOI: 10.1016/j.ejca.2005.07.027

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Authors:  Franck Bourdeaut; Sandrine Ferrand; Laurence Brugières; Marjorie Hilbert; Agnès Ribeiro; Ludovic Lacroix; Jean Bénard; Valérie Combaret; Jean Michon; Dominique Valteau-Couanet; Bertrand Isidor; Xavier Rialland; Maryline Poirée; Anne-Sophie Defachelles; Michel Peuchmaur; Gudrun Schleiermacher; Gaëlle Pierron; Marion Gauthier-Villars; Isabelle Janoueix-Lerosey; Olivier Delattre
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

2.  Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities.

Authors:  Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tracy Kaluzny; Wayne L Furman; Matthew W Wilson
Journal:  Pediatr Blood Cancer       Date:  2016-07-13       Impact factor: 3.167

3.  A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families.

Authors:  Wenhui L Li; Jonathan Buckley; Pedro A Sanchez-Lara; Dennis T Maglinte; Lucy Viduetsky; Tatiana V Tatarinova; Jennifer G Aparicio; Jonathan W Kim; Margaret Au; Dejerianne Ostrow; Thomas C Lee; Maurice O'Gorman; Alexander Judkins; David Cobrinik; Timothy J Triche
Journal:  J Mol Diagn       Date:  2016-05-04       Impact factor: 5.568

4.  Lack of correlation between age at diagnosis and RB1 mutations for unilateral retinoblastoma: the importance of genetic testing.

Authors:  Jesse L Berry; Laura Lewis; Emily Zolfaghari; Sarah Green; Bao Han A Le; Thomas C Lee; A Linn Murphree; Jonathan W Kim; Rima Jubran
Journal:  Ophthalmic Genet       Date:  2017-12-29       Impact factor: 1.803

Review 5.  Germline genetic landscape of pediatric central nervous system tumors.

Authors:  Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

6.  Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture.

Authors:  Markus Hassler; Shradha Singh; Wyatt W Yue; Maciej Luczynski; Rachid Lakbir; Francisco Sanchez-Sanchez; Thomas Bader; Laurence H Pearl; Sibylle Mittnacht
Journal:  Mol Cell       Date:  2007-11-09       Impact factor: 17.970

7.  Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.

Authors:  Yoonsoo Park; Akihito Kubo; Takefumi Komiya; Amy Coxon; Kristin Beebe; Len Neckers; Paul S Meltzer; Frederic J Kaye
Journal:  Cell Cycle       Date:  2008-05-30       Impact factor: 4.534

Review 8.  Molecular biology of retinoblastoma.

Authors:  C Sábado Alvarez
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

9.  A comprehensive, sensitive and economical approach for the detection of mutations in the RB1 gene in retinoblastoma.

Authors:  Vidya Latha Parsam; Chitra Kannabiran; Santosh Honavar; Geeta K Vemuganti; Mohammad Javed Ali
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

10.  Variability in retinoblastoma genome stability is driven by age and not heritability.

Authors:  Ashley Polski; Liya Xu; Rishvanth K Prabakar; Xiaowu Gai; Jonathan W Kim; Rachana Shah; Rima Jubran; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry
Journal:  Genes Chromosomes Cancer       Date:  2020-06-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.